Background: Ag85 is a protein that may maintain survival of M. tuberculosis in intracellular parts of host cells and is considered as a virulence factor. The expression of Ag85 protein can stimulate proliferation and differentiation of B-cells and T-cells in patients with tuberculosis. This research aimed to determine the ability of Ag85A and Ag85B proteins in activating the response of antibodies, granzyme-B and perforin in Balb/c mice. Materials and Methods: Twenty-five male Balb/c mice were assigned into five groups. Group I was treated with adjuvant, group II with Bacillus Calmette-Guerin (BCG) vaccine, group III with a combination of BCG and Ag85A, group IV with a combination of BCG and Ag85B and group V with a combination of BCG, Ag85A and Ag85B. Concentrations of immunoglobulin G, granzyme-B and perforin were examined using ELISA and the number of CD8+ T-cells and NK T-cells were checked by flow cytometry.
Introduction
Tuberculosis remains a major global health problem because its effective treatment and diagnosis are not established yet (Guggino et al., 2015) . Globally, over 10.0 million people that predominately lived in developing countries were infected by tuberculosis in 2017, with a mortality rate of 1.3 million people (WHO, 2016) . Bacillus Calmette-Guerin (BCG) vaccination and Directed Observed Treatment Short-course (DOTS) programs are still applied to prevent and treat tuberculosis. Administration of BCG vaccine as a preventive measure for tuberculosis does not provide significant effects and has an efficacy of 0-80% (Otu, 2013; McBryde et al., 2016; O'Shea et al., 2016) . BCG vaccine is effective in miliary tuberculosis or meningitis prevention for children, but does not provide protection in pulmonary tuberculosis for adults with latent tuberculosis and reactivation (Piubelli et al., 2013) . Increasing number of Multi Drugs Resistant (MDR) tuberculosis and HIV-related infections cause the cases to be more complex, making the disease increasingly difficult to eliminate. The emergence of MDR tuberculosis and the presence of undetected new cases make tuberculosis transmission chain even more uncontrolled (McBryde et al., 2016; O'Shea et al., 2017) .
The minimum protection of the BCG vaccine in overcoming tuberculosis transmission and epidemics has encouraged continuous efforts to find new candidate vaccines (Dietrich et al., 2014) . Development of better diagnostic tools and the use of new vaccines are two main pillars to reduce MDR TB cases (Horwitz et al., 2000) . The discovery of new, more effective vaccine candidates, including the vaccine sub-unit, is an effort that has been done to control and eliminate tuberculosis (Jiang et al., 2013) . A main fraction of the excretory protein of M. tuberculosis and M. bovis BCG culture filtrate is the Ag85 complex. Secreted antigen 85 (Ag85) protein is present on the cell wall surface and needed for the survival of M. tuberculosis in macrophages and is considered a virulence factor. Three members of Ag85 protein with molecular weights of 30-32 kDa: Ag85A, Ag85B and Ag85C that are encoded by three paralogous genes: fbpA, fbpB and fbpC, are located in different regions of the bacterial genome (Kuo et al., 2013) .
Ag85 is known as a protein that can maintain survival of M. tuberculosis in intracellular parts of host cells and helps the bacteria defend themselves against the immune system while facilitating the formation of tubercles (Launois et 
Materials and Methods

Animal models
In this research, twenty-five (n=25) male Balb/c mice (8-10 weeks old, 20-30 g) were obtained and kept at the animal experimental laboratory of LPPT Universitas Gadjah Mada. Ethical clearance for use of animals in research was obtained from the Ethical Clearance Commission of the Faculty of Veterinary Medicine, Universitas Gadjah Mada (Approval Number: 0021/EC-FKH/Eks/2018). The mice were kept in standard conditions as demanded by humane protocol and each cage contained five Balb/c mice.
Preparation of Ag85 recombinant protein
Ag85A and Ag85B genes were inserted into pET SUMO plasmid (InvitrogenTM ChampionTM pET SUMO Cat Protein Expression System No. K300-01) and were transformed into E. coli BL21 (DE3). Ag85 recombinant genes were expressed in liquid LB medium containing kanamycin (50 µg/ml), and induced with 1 mM isopropyl-beta-D-thiogalactopyranoside (IPTG). Ag85A and Ag85B recombinant proteins were then purified by Ni-NTA purification system kit (InvitrogenTM NovexTM Cat No.K950-01). The purified proteins were cleaved, using protease to separate the SUMO taq protein in SUMO and Ag85 recombinant proteins, and stored at -20 0 C.
Immunization of Balb/c mice
Immunogenicity of Ag85 recombinant proteins of M. tuberculosis was measured in Balb/c mice that had been immunized by Ag85A and Ag85B proteins. The expressions of the Balb/c mice antibodies and cellular immune responses were analyzed. The animals were assigned into five groups, which consisted of five Balb/c mice per group. Group I was treated with adjuvant, group II with BCG vaccine (Bio Farma Bandung), group III with a combination of BCG and Ag85A, group IV with a combination of BCG and Ag85B, and group V with a combination of BCG, Ag85A and Ag85B. Initially, Balb/c mice were vaccinated by using 0.2 ml of recombinant proteins containing 10 µg of Ag85A and Ag85B, which was supplemented with Complete Freund Adjuvant (1:1) intraperitoneally in groups III, IV and V. Booster was done every two weeks for three times with 5 µg of an antigen supplemented with Incomplete Freund Adjuvant. The same treatment was also given to the control group (Chen et al., 2006) . Animals were euthanized based on Institutional Animal Care and Use Committee (IACUC) by using the Cervical Dislocation method. Lymphocytes (splenocytes) from the lymph of Balb/c mice were then isolated for further examination of CD8+ T-cells and NK cells using flow cytometry methods.
Serum collection and ELISA assay
Blood samples of Balb/c mice were obtained through the sinus orbital bleeding. Previously, mice were anesthetized with 40 mg/kg BW ketamine (IACUC standard). Blood samples were kept in 1.5 ml microcentrifuge tube, and subjected to centrifuge at 6,000 rpm for 10 minutes. The serum obtained was examined for immunoglobulins, granzyme-B and perforin. Immunoglobulin examination was conducted by using anti-mouse IgG (H + L) AP secondary antibody (Invitrogen (2010) . Cat No.A16069). Perforin was examined by using mouse perforin/pore-forming ELISA kit protein (Cat Bioassay technology -No. E0999Mo); while granzyme-B was examined by using mouse granzyme-B ELISA kit (Affymetrix ebioscience -BMS 6029).
Isolation of splenocytes in Balb/c mice and flow cytometry assay
Spleens of Balb/c mice were aseptically isolated, and transferred into sterile petri dishes containing RPMI 1640 culture medium. Cells were removed from the spleen by RPMI 1640 medium spraying using a syringe repeatedly. The cells suspension was moved into a-15 ml conical tube and centrifuged at 5,000 rpm for 5 minutes. The erythrocytes were lyzed with 1 ml ammonium chloride (NH4Cl) solution for 3 minutes, and then centrifuged at 5,000 rpm for 5 minutes. Lymphocytes were dissolved in RPMI 1640 medium, and centrifuged at 5,000 rpm for 5 minutes. The pellets were dissolved in 100 µl PBS, and transferred 50 µl solution to a new tube and mixed with 5 µl of anti-mouse CD8+ FITC/anti-mouse CD49b FITC monoclonal antibody. The solution was incubated for 30 minutes at room temperature in a dark condition. It was then subjected for flow cytometry assay (FACS Calibur, Beckton Dickinson, San Jose, CA) and analyzed by using CELL QUEST software (Beckton Dickinson).
Statistical Analysis
All values were presented as means ± standard deviations. Numerical data were analyzed using One-way ANOVA test for normally distributed and homogeneous data. Data analysis was performed by using SPSS 16.0 software with a confidence level of 95 %. Differences were considered as statistically significant at p< 0.05 values.
Results
Recombinant Ag85A and Ag85B proteins were expressed in the BL21 (DE3) competent E. coli expression system. Figure 1 shows that Ag85A and Ag85B have 36 kDa and 34 kDa molecular weights, respectively. This confirmed that the recombinant Ag85A and Ag85B were appropriate for further in vivo analysis. Intra-peritoneal administrations of recombinant Ag85A and Ag85B proteins induced the antibody production against Ag85A and Ag85B in Balb/c mice ( Figure 2) . The results showed that the antibody expression was significantly higher in mice treated with combination of BCG and Ag85A or Ag85B and both recombinant proteins compared to the untreated and BCG treated mice (p=0.001). Recombinant Ag85A and Ag85B proteins clearly have immunogenicity effect in Balb/c mice. The mean number of CD8+ T-cells in Balb/c mice induced by adjuvant, BCG, BCG combined with Ag85A, BCG combined with Ag85B, and BCG combined with both of Ag85 A and Ag85B were 1.03%, 3.18%, 3.28%, 4.32% and 3.61%, respectively (Figure 3) . The mean numbers of NK cells were 0.37%, 0.5%, 0.72%, 1.03% and 0.85%, respectively (Figure 4) . The scatter plot indicated that, the highest percentage of CD8+ T-cells and NK cells number were observed in the combination of BCG and Ag85B groups. The One-Way ANOVA test showed that the mean number of CD8+ T-cells and NK cells were significantly higher in mice treated with combination of BCG and Ag85A or Ag85B and both recombinant proteins compared to the untreated and BCG treated mice (p=0.001 and p=0.035), respectively. Whereas, the mean number of CD8+ T-cells and NK cells were not significantly different in mice treated with combination of BCG and Ag85A compared to the combination BCG and Ag85B or both recombinant proteins, with a value of p >0.05 (p=0.14 and p=0.11), respectively. Results of ELISA test of granzyme-B and perforin on each of the groups I, II, III, IV and IV were 24.25 pg/ml and 3. 55 pg/ml, 29.33 pg/ml and 4.84 pg/ml, 34.4 pg/ml and 5.59 pg/ml, 35.11 pg/ml and 6.19 pg/ml as well as 34.45 pg/ml and 5.88 pg/ml, respectively.
These results indicated that the highest concentrations of granzyme-B and perforin were found in the group induced with BCG and Ag85B. The concentrations of granzyme-B and perforin were significantly higher in mice treated with combination BCG and Ag85A or Ag85B and both combination proteins compared to untreated mice. Statistical tests showed no significant differences in the levels of granzyme-B and perforin in mice treated with combination BCG and Ag85A or Ag85B and both recombinant proteins compare to BCG treated mice, with a value of p>0,05 (p=0,.06 and p=0.10), respectively.
Discussion
Various efforts have been made to control and prevent morbidity and mortality of patients infected with M. tuberculosis. Discovery of a new vaccine candidate with high antigenicity in improving the immune response was one of the efforts that continues to be developed (Aghababa et al., 2011) . Several M. tuberculosis excretory proteins play important roles in the pathogenesis of the disease and act as immunostimulants that directly interact with the host's immune system. Ag85A and Ag85B proteins of M. tuberculosis proteins are some of the candidates that could be used for the development of TB vaccines. Recombinant Ag85 proteins of M. tuberculosis have been shown as a promising approach (Zvi et al., 2008; Kuo et al., 2013) . In this study, our Ag85A and Ag85B recombinant proteins expressed in BL21 (DE3) competent E. coli cells showed functional properties to induce immune response in Balb/c mice.
The results of the immune response tests of Ag85A and Ag85B proteins on the experimental animals used showed that a significant increase in immune response (p<0.05) after Balb/c mice were administered a combination of Ag85 recombinant protein compared to the BCG vaccinated only group. The combination of BCG and Ag85B had the highest antigenic activity in stimulating antibody formation in Balb/c mice. Ag85B proteins with a molecular weight of 34 kDa were the dominant antigen and responsible for almost 25% of the total extracellular protein. Vaccinations of the experimental animals that were induced with Ag85B gave significant protective immunity to the exposure against M. tuberculosis compared to the conventional M. bovis BCG vaccine. The study conducted by Li et al. (2015) in female ICR mice demonstrated an enhanced T-cell response and increased production of cytokines, including interferon-γ, tumor necrosis factor-α and interleukin-2 in mice treated with a combination of BCG and recombinant adenoviral vector (Ad5-CEAB) co-expressing Ag85 and culture filtrate protein, compared to treatment with BCG alone. In addition, the subjects of this study demonstrated to have a humoral response with increased concentrations of secretory immunoglobulin A(sIgA) and serum immunoglobulin G(IgG) in mice treated with a combination of BCG and recombinant adenoviral vector (Ad5-CEAB), compared to treatment with BCG alone. The study conducted by Tanghe 
Conclusion
Ag85A and Ag85B proteins act as immunogenic agents, that could increase immunoglobulin response and the number of CD8+ T-cells and NK-cells in Balb/c mice induced by BCG combined with recombinant proteins. However, they could not activate CD8+ T-cells and NK-cells to express granzyme-B and perforin significantly.
